JWCA
NRIX icon

J.W. Cole Advisors’s Nurix Therapeutics NRIX Stock Holding History

J.W. Cole Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,028
Closed -$265K – 927
2024
Q1 		$265K Buy
+18,028
New +$194K 0.01% 737

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

J.W. Cole Advisors's NRIX Position: Q2 2024 in Review

J.W. Cole Advisors sold out of Nurix Therapeutics (NRIX) in Q2 2024, closing a stake of 18,028 shares — an estimated $265K sold.

J.W. Cole Advisors first reported a position in NRIX in Q1 2024 and held it in 1 quarter. The position peaked at $265K in Q1 2024. 173 funds tracked by Wall St. Rank hold NRIX as of Q2 2024.

  • J.W. Cole Advisors reported no remaining Nurix Therapeutics position as of Q2 2024 after selling out during the quarter.
  • J.W. Cole Advisors sold 18,028 Nurix Therapeutics shares in Q2 2024, an estimated $265K.
  • J.W. Cole Advisors first reported a position in Nurix Therapeutics in Q1 2024 and held it in 1 quarter.
  • J.W. Cole Advisors's Nurix Therapeutics position peaked at $265K in Q1 2024.
  • 173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2024.

Based on J.W. Cole Advisors's 13F filing for Q2 2024, filed 8 Aug 2024.